Retinal Implant Restores Some Sight to Blind

Researchers Say Implanted Microchip Allows 3 Patients to Recognize Some Shapes

Medically Reviewed by Laura J. Martin, MD on November 03, 2010
From the WebMD Archives

Nov. 3, 2010 -- Three blind patients treated with an experimental eye implant were able to see shadows and shapes after getting the device, raising hopes that a highly anticipated new approach to treating blindness may be on the horizon.

Eberhart Zrenner, MD, of Germany’s University of Tubingen Eye Hospital, says close to 30 research groups are working on retinal implants designed to restore sight to the blind; Zrenner’s study is one of only two that have been tried in humans.

The three patients included in the newly published report had gone blind as a result of hereditary retinal degeneration.

Within days of having a tiny microchip surgically implanted, the two men and one woman could see shadows and were able to recognize some shapes.

One man was able to recognize that his fiancée was smiling at him, Zrenner tells WebMD.

How the Implant Works

The microchip, which is just slightly bigger than a sesame seed, includes 1,500 light sensors connected to amplifiers and electrodes. The microchip is designed to sense light and -- with the help of still functioning neurons in the retina -- transmit light signals to the brain.

The implants are controlled by a small handheld external unit, which receives signals from a coin-sized device implanted under the skin directly behind the ear. This device is connected to the chip in the retina, Zrenner says.

The retinal implant allows patients to distinguish between highly contrasting light and dark images. The idea is that the brain can learn to interpret these lines and shapes into meaningful images.

A total of 11 patients received the chip device in the pilot study starting in 2005, but the researchers changed the placement the chip in the retina after the first eight patients were treated in an effort to improve outcomes.

According to the report in the journal Proceedings of the Royal Society B, the last three patients treated were able locate bright objects on a dark table after receiving the implant, and two of the three could name some specific objects the first time they saw them.

One patient could describe objects like forks and knives and different kinds of fruit on the table, as well as correctly identify large, white shapes and letters placed on a black background.

“This was certainly not normal vision,” Zrenner says. “But for people who have been completely blind for years, even this limited improvement can make a difference.”

Larger Study Underway

The device was developed with funding from the German government and Retinal Implant AG, a company Zrenner founded and now directs.

The company is now conducting a two-year study that will include 25 to 50 patients.

Zrenner says if all goes well the retinal implant could be commercially available within three to five years for use in people blinded by a genetic eye condition known as retinitis pigmentosa.

About one in 4,000 people worldwide have the condition and about one in 10 cases of blindness are caused by the hereditary disorder.

The California-based company Second Sight Medical Products is testing a different type of retinal implant that includes a camera and transmitter mounted on special eyeglasses.

In the spring of 2009, the company announced that it had received FDA approval to implant its device in 20 people blinded by retinitis pigmentosa.

Stephen Rose, PhD, who is chief research officer for the Foundation Fighting Blindness, says the excitement surrounding retinal implants is understandable.

“This would represent a great advance for people with no retained vision,” he tells WebMD. “It could provide them with some sight and the promise of much more as the technology advances.”

He is optimistic that such advances will lead to retinal implants that can restore even more functional sight to blind patients, possibly within a decade.

“These people won’t be driving, but they could be able to read with the help of large-print readers, just as people with low vision do today,” he says.

WebMD Health News



Zrenner, E. Proceedings of the Royal Society B, Oct. 3, 2010; online edition.

Eberhart Zrenner, executive director, University Eye Hospital, University of Tubingen, Germany; director, Retinal Implant AG.

Stephen Rose, PhD, chief research officer, Foundation Fighting Blindness.

News release, Second Sight, May 4, 2009.

© 2010 WebMD, LLC. All rights reserved.
Click to view privacy policy and trust info